Elevation Oncology Files Proxy Materials
| Field | Detail |
|---|---|
| Company | Elevation Oncology, Inc. |
| Form Type | DEFA14A |
| Filed Date | Apr 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy, SEC filing, corporate governance
TL;DR
Elevation Oncology dropped proxy docs. Standard stuff.
AI Summary
Elevation Oncology, Inc. filed a Definitive Additional Materials (DEFA14A) on April 24, 2025. This filing relates to their proxy statement and is for the fiscal year ending December 31, 2024. The company, formerly known as 14ner Oncology, Inc., is based in Boston, MA.
Why It Matters
This filing is a routine but essential part of corporate governance, informing shareholders about company matters and their voting rights.
Risk Assessment
Risk Level: low — This is a standard proxy filing, not indicating any immediate financial or operational risks.
Key Players & Entities
- Elevation Oncology, Inc. (company) — Registrant
- 14ner Oncology, Inc. (company) — Former company name
- 0001558370-25-005419 (filing_id) — Accession Number
- 20250424 (date) — Filing Date
- 1231 (date) — Fiscal Year End
FAQ
What type of filing is this?
This is a Definitive Additional Materials (DEFA14A) filing.
Who is the filing company?
The filing company is Elevation Oncology, Inc.
When was this filing made?
The filing was made on April 24, 2025.
What is the company's former name?
The company's former name was 14ner Oncology, Inc.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 24, 2025 regarding Elevation Oncology, Inc..